144 related articles for article (PubMed ID: 38899172)
41. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review.
Franceschini N; North KE; Kopp JB; McKenzie L; Winkler C
Genet Med; 2006 Feb; 8(2):63-75. PubMed ID: 16481888
[TBL] [Abstract][Full Text] [Related]
42. Pre-emptive rituximab in focal and segmental glomerulosclerosis patients at risk of recurrence after kidney transplantation.
Auñón P; Polanco N; Pérez-Sáez MJ; Rodrigo E; Sancho A; Pascual J; Andrés A; Praga M
Clin Kidney J; 2021 Jan; 14(1):139-148. PubMed ID: 33564412
[TBL] [Abstract][Full Text] [Related]
43. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
Agrawal V; Prasad N; Jain M; Pandey R
Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
[TBL] [Abstract][Full Text] [Related]
44. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.
Sinha A; Mathew G; Arushi A; Govindarajan S; Ghanapriya K; Grewal N; Rai K; Brijwal M; Kalluru SL; Tewari P; Misra A; Khandelwal P; Hari P; Bagga A
Nephrol Dial Transplant; 2023 Mar; 38(4):939-949. PubMed ID: 36071552
[TBL] [Abstract][Full Text] [Related]
45. Rituximab for refractory focal segmental glomerulosclerosis.
Nakayama M; Kamei K; Nozu K; Matsuoka K; Nakagawa A; Sako M; Iijima K
Pediatr Nephrol; 2008 Mar; 23(3):481-5. PubMed ID: 17973121
[TBL] [Abstract][Full Text] [Related]
46. Morphologic Analysis of Urinary Podocytes in Focal Segmental Glomerulosclerosis.
Shirai Y; Miura K; Yokoyama T; Horita S; Nakayama H; Seino H; Ando T; Shiratori A; Yabuuchi T; Kaneko N; Ishiwa S; Ishizuka K; Hara M; Hattori M
Kidney360; 2021 Mar; 2(3):477-486. PubMed ID: 35369007
[TBL] [Abstract][Full Text] [Related]
47. New Anti-Nephrin Antibody Mediated Podocyte Injury Model Using a C57BL/6 Mouse Strain.
Takeuchi K; Naito S; Kawashima N; Ishigaki N; Sano T; Kamata K; Takeuchi Y
Nephron; 2018; 138(1):71-87. PubMed ID: 28965116
[TBL] [Abstract][Full Text] [Related]
48. Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.
Marasà M; Cravedi P; Ruggiero B; Ruggenenti P
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25155494
[TBL] [Abstract][Full Text] [Related]
49. Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy.
Nara M; Kaga H; Saito M; Abe F; Saito A; Imaizumi C; Komatsuda A; Wakui H; Takahashi N
Intern Med; 2021 Sep; 60(18):2985-2989. PubMed ID: 33776000
[TBL] [Abstract][Full Text] [Related]
50. Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience.
Kim J; Patnaik N; Chorny N; Frank R; Infante L; Sethna C
Nephron Extra; 2014 Jan; 4(1):8-17. PubMed ID: 24575119
[TBL] [Abstract][Full Text] [Related]
51. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.
Kemper MJ; Valentin L; van Husen M
Pediatr Nephrol; 2018 Oct; 33(10):1641-1649. PubMed ID: 28879428
[TBL] [Abstract][Full Text] [Related]
52. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
Kamei K; Ishikura K; Sako M; Ito S; Nozu K; Iijima K
Pediatr Nephrol; 2020 Jan; 35(1):17-24. PubMed ID: 30564879
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.
Xue C; Yang B; Xu J; Zhou C; Zhang L; Gao X; Dai B; Yu S; Mao Z; Mei C; Xu C
Clin Kidney J; 2021 Apr; 14(4):1042-1054. PubMed ID: 34094516
[TBL] [Abstract][Full Text] [Related]
54. Reply to Angeletti et al-Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis.
Dossier C; Hogan J
Am J Transplant; 2024 Feb; ():. PubMed ID: 38387621
[No Abstract] [Full Text] [Related]
55. Different effects of rituximab on a native kidney and a post-transplant kidney with recurrence of focal segmental glomerulosclerosis.
Ino A; Kaori S; Takei T; Nitta K
CEN Case Rep; 2020 Aug; 9(3):195-199. PubMed ID: 31997159
[TBL] [Abstract][Full Text] [Related]
56. Glomerular parietal epithelial expression of CD44 in minimal change nephrotic syndrome and primary focal segmental glomerulosclerosis: A clinico-pathological study.
Paul EN; Satish S; Kelur KK; Shetty MS
Indian J Pathol Microbiol; 2023; 66(3):526-532. PubMed ID: 37530333
[TBL] [Abstract][Full Text] [Related]
57. Is rituximab effective in childhood nephrotic syndrome? Yes and no.
Kemper MJ; Lehnhardt A; Zawischa A; Oh J
Pediatr Nephrol; 2014 Aug; 29(8):1305-11. PubMed ID: 23820888
[TBL] [Abstract][Full Text] [Related]
58. Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis.
Wee Leng G; Mustafar R; Kamaruzaman L; Mohd R; Cader RA; Wei Yen K; Kiew Bing P
Acta Med Indones; 2018 Jul; 50(3):237-243. PubMed ID: 30333274
[TBL] [Abstract][Full Text] [Related]
59. Rituximab in idiopathic nephrotic syndrome: does it make sense?
Cara-Fuentes G; Kairalla JA; Ishimoto T; Rivard C; Johnson RJ; Garin EH
Pediatr Nephrol; 2014 Aug; 29(8):1313-9. PubMed ID: 23793923
[TBL] [Abstract][Full Text] [Related]
60. Repeated Administrations of Rituximab along with Steroids and Immunosuppressive Agents in Refractory Steroid-resistant Nephrotic Syndrome.
Fujinaga S; Sakuraya K
Indian Pediatr; 2017 Jan; 54(1):49-50. PubMed ID: 28141565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
